ABSTRACT
The change of human cytochrome P450 1A2 ontogeny and the effect of its gene polymorphism on clinical medication were reviewed. The relevant literatures from various databases were searched, collected, analyzed and summarized. CYP1A2 is one of the major subfamilies in human liver enzyme. It is involved in metabolism of about 8%-10% of drugs in clinic, which has important pharmacological and toxicological implications.The expression and activity of CYP1A2 enzymes were different during development, which had a significant effect on clinical medication in human. Studies can see clearance rates and elimination half-lives differences by using caffeine as a probe substrate.Gene polymorphisms cause activity differences of CYP1A2. Gene polymorphisms of CYP1A2*1C and CYP1A2*1F, have been extensively studied show significant effects on clinical medication in adults.There are very few studies on medication between CYP1A2 gene polymorphism and enzyme activity in premature infants, infants and children. The effect of CYP1A2 enzyme activity is unknown between gene polymorphism and ontogeny interaction during human development.It is very necessary to further study the ontogeny changes of CYP1A2 and its gene polymorphism on drug metabolism for improving the safety and efficacy medication in children.